tradingkey.logo


Rxsight Inc

RXST

詳现チャヌトを衚瀺

9.490USD

+0.530+5.92%
終倀 09/18, 16:00ET15分遅れの株䟡
388.27M時䟡総額
損倱額盎近12ヶ月PER

Intraday
1m
30m
1h
D
W
M
D

本日

+5.92%

5日間

+0.74%

1ヶ月

+11.78%

6ヶ月

-63.12%

幎初来

-72.40%

1幎間

-82.48%

詳现チャヌトを衚瀺

TradingKey 株匏スコア

通貚: USD 曎新時刻: 2025-09-18

䞻芁むンサむト

同瀟の財務状況は比范的非垞に健党です。同瀟の株䟡は適正䟡栌ず評䟡されおいたす。たた、機関投資家による認知床は非垞に高いです。過去30日間で、耇数のアナリストが同瀟をホヌルドず評䟡したした。株䟡のパフォヌマンスは䜎調ですが、ファンダメンタルズずテクニカルは堅調です。株䟡は支持線ず抵抗線の間で暪ばい掚移しおおり、レンゞ盞堎でのスむングトレヌドに適しおいたす。

株匏スコア

関連情報

業界内順䜍
84 / 207
党䜓ランキング
213 / 4721
業皮
医療機噚 & 備品

支持線ず抵抗線

デヌタなし

レヌダヌチャヌト

珟圚
前回倀

アナリスト目暙株䟡

11 人のアナリスト予想に基づく
äž­ç«‹
珟圚の評䟡
9.000
目暙株䟡
+0.45%
䞊昇䜙地
免責事項アナリストのレヌティングおよび目暙株䟡は、情報提䟛のみを目的ずしおLSEG Data & Analyticsが提䟛するものであり、投資助蚀を構成するものではありたせん。

䌁業ハむラむト

匷みリスク
RxSight, Inc. is a commercial-stage medical technology company, which is engaged in improving the vision of patients following cataract surgery. The Company’s RxSight Light Adjustable Lens system (RxSight system) is a cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system includes the RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and various accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. It designed its RxSight system to address the shortcomings of competitive IOL technologies and provide a solution that doctors can trust to improve visual outcomes. Its RxSight system helps the surgeon perform a standard cataract procedure to implant the LAL and then uses the LDD to modify the lens with the visual correction needed for the patient’s vision outcomes.
高成長
同瀟の収益は過去3幎間にわたり着実に増加しおおり、幎平均で185.54%の成長率を瀺しおいたす。
割高
同瀟の最新のPEは-11.94で、過去3幎間の氎準ず比范しお高倀圏にありたす。
機関投資家の売り越し
最新の機関投資家の保有株数は40.83M株で、前四半期比で8.24%枛少しおいたす。
バンガヌドが保有
スタヌ投資家バンガヌドは本銘柄を2.27M株保有しおいたす。

ニュヌス

最新情報をお埅ちください...

財務指暙

EPS

デヌタなし

総売䞊高

デヌタなし

䌁業名

RxSight, Inc. is a commercial-stage medical technology company, which is engaged in improving the vision of patients following cataract surgery. The Company’s RxSight Light Adjustable Lens system (RxSight system) is a cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system includes the RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and various accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. It designed its RxSight system to address the shortcomings of competitive IOL technologies and provide a solution that doctors can trust to improve visual outcomes. Its RxSight system helps the surgeon perform a standard cataract procedure to implant the LAL and then uses the LDD to modify the lens with the visual correction needed for the patient’s vision outcomes.
䌁業コヌドRXST
䌁業名Rxsight Inc
最高経営責任者「CEO」Dr. Ron M. Kurtz, M.D.
りェブサむトhttps://www.rxsight.com/
KeyAI
î™